Jefferies Group LLC reaffirmed their hold rating on shares of Novozymes A/S – (NASDAQ:NVZMY) in a research report released on Thursday morning. Jefferies Group LLC currently has a $54.97 price objective on the biotechnology company’s stock.
Separately, Zacks Investment Research raised shares of Novozymes A/S – from a hold rating to a strong-buy rating and set a $52.00 price target for the company in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $57.99.
Novozymes A/S – (NASDAQ NVZMY) traded up 0.42% during midday trading on Thursday, hitting $54.79. The stock had a trading volume of 17,415 shares. The stock’s 50-day moving average is $51.99 and its 200-day moving average is $46.85. Novozymes A/S – has a one year low of $31.57 and a one year high of $55.14. The company has a market cap of $16.17 billion and a P/E ratio of 33.23.
Novozymes A/S – (NASDAQ:NVZMY) last announced its quarterly earnings results on Friday, August 11th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by ($0.03). The firm had revenue of $522.72 million for the quarter. Equities analysts predict that Novozymes A/S – will post $1.68 EPS for the current fiscal year.
Novozymes A/S – Company Profile
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America.
What are top analysts saying about Novozymes A/S -? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novozymes A/S - and related companies.